1-Butyloxy-4-methyl-cyclohexan | 91242-76-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-Butyloxy-4-methyl-cyclohexan
• 英文别名: 4-Butyloxy-1-methyl-cyclohexan；4-Butoxy-methylcyclohexan；1-Butoxy-4-methylcyclohexane
• CAS: 91242-76-1
• 化学式: C₁₁H₂₂O
• 分子量: 170.295
• InChiKey: WRQPOYYTCJFQDQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  正溴丁烷 、 4-甲基环己醇 生成 1-Butyloxy-4-methyl-cyclohexan
  参考文献：
  名称：

  Vinyl compounds in the diene synthesis

  摘要：

  DOI：

  10.1007/bf00908401

文献信息

• Verification of translation
  申请人：Inagaki Jyun-ichi

  公开号：US20070190344A1

  公开（公告）日：2007-08-16

  A compound represented by Formula (1) and a polymer obtained using the compound: wherein R 1 is phenyl which may have substituents, Q 1 is hydrogen, halogen, alkyl having 1 to 10 carbon atoms, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl or phenyl in which optional hydrogen may be replaced by halogen or alkyl having 1 to 5 carbon atoms, Q 2 is a group represented by Formula (2): wherein the code < represents a bonding point with silicon, l, m, n and p are independently 0, 1, 2 or 3, and A 1 to A 4 , Z 0 to Z 4 and Y 1 are defined in the specification.

  公式（1）所表示的化合物和使用该化合物制得的聚合物：其中R1是苯基，可以有取代基；Q1是氢、卤素、具有1至10个碳原子的烷基、环丙基、环丁基、环戊基、环己烯基或苯基，其中可选氢原子可以被卤素或具有1至5个碳原子的烷基所取代；Q2是由公式（2）表示的基团：其中代码<表示与硅的连接点，l、m、n和p独立地为0、1、2或3，A1至A4、Z0至Z4和Y1在规范中有定义。
• TETRACYCLIC INHIBITORS OF JANUS KINASES
  申请人：Rodgers James D.

  公开号：US20090215766A1

  公开（公告）日：2009-08-27

  The present invention provides compounds that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer.

  本发明提供了一种可以调节Janus激酶活性的化合物，这些化合物可用于治疗与Janus激酶活性相关的疾病，例如免疫相关疾病和癌症。
• 5-ALKOXY-2(3H)-OXAZOLONE COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF
  申请人：Ube Industries, Ltd.

  公开号：EP0945448B1

  公开（公告）日：2008-11-26
• OPTICAL FILM, CIRCULARLY POLARIZING PLATE, AND IMAGE DISPLAY DEVICE
  申请人：Fujisawa Rie

  公开号：US20150247963A1

  公开（公告）日：2015-09-03

  A optical film includes a thermoplastic resin and a compound wherein: (1) the absorption spectrum of said compound in solution has at least two absorption maxima in the 200-350 nm wavelength range; (2) letting λmax 1 represent the wavelength of a first absorption maximum (one of the aforementioned absorption maxima) and letting λmax 2 represent the wavelength of a second absorption maximum (another of the aforementioned absorption maxima) at a shorter wavelength than the first absorption maximum, (λmax 1 −λmax 2 ) is at least 20 nm; (3) the aspect ratio of the molecules of the compound is at least 1.70; (4) each molecule of the compound has a non-aromatic hydrocarbon ring, a non-aromatic heterocycle, or an aromatic heterocycle; (5) the in-plane-retardation increase sensitivity of the compound is at least 0.1; 110 nm≦R 0 (550)≦170 nm; 0.72≦R 0 (450)/R 0 (550)≦0.96; and 0.83≦R 0 (550)/R 0 (650)≦0.97.
• NOVEL SIGMA RECEPTOR LIGANDS AND METHODS OF MODULATING CELLULAR PROTEIN HOMEOSTASIS USING SAME
  申请人：DREXEL UNIVERSITY

  公开号：US20160361279A1

  公开（公告）日：2016-12-15

  The present invention includes compounds useful in preventing, treating or ameliorating Sigma-related disorders or diseases. The compounds of the invention may modulate cellular protein homeostasis, which includes: translation initiation, folding, processing, transport, and degradation (including ubiquitin selective autophagy) of proteins. The present invention also includes methods of preventing, treating or ameliorating a Sigma-related disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Sigma-modulating compound. The present invention also includes methods of preventing, treating or ameliorating a Sigma-related disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Sigma-modulating compound, further comprising administering an effective amount of a compound that inhibits the ubiquitin proteasome system (UPS) and/or autophagic survival pathways.